Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats.
The substituted amphetamines 4-chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) and fenfluramine (FEN) share the common neurochemical action of acutely releasing central serotonin (5-HT), and yet their behavioral effects are quite different. The present study evaluated the effects of these compounds on acoustic and tactile startle reflexes. PCA and MDMA were qualitatively similar in producing dose-related increases in acoustic and tactile startle reflexes that were slow in onset, but sustained throughout the 3.5-hr test session. Changes in motor activity did not account for the observed excitation of startle. In marked contrast to MDMA and PCA, FEN did not alter tactile startle and tended to depress acoustic startle. The excitatory effect of 20 mg/kg of MDMA was prevented by the 5-HT uptake blockers MDL 27,777A and fluoxetine. MDMA excitation was not affected by a dose of the dopamine antagonist haloperidol that attenuated the startle-enhancing effect of d-amphetamine. MDMA excitation was greatly attenuated by a general depletion of central 5-HT produced by prior intraventricular injection of the 5-HT neurotoxin 5,7-dihydroxytryptamine. PCA and MDMA excitations of startle were attenuated in rats specifically depleted of spinal 5-HT or in rats with radio frequency lesions of the dorsal raphe nucleus. Thus, PCA and MDMA have similar prolonged excitatory effects on startle reflexes that are mediated by ascending (dorsal raphe) and descending (spinal) pathways, whereas FEN differs in its lack of excitation of startle. Differences in the neurochemical properties of these compounds or their patterns of 5-HT release may underlie their different behavioral profiles.
Kehne
J H
JH
Marion Merrell Dow Research Institute, Cincinnati, Ohio.
McCloskey
T C
TC
Taylor
V L
VL
Black
C K
CK
Fadayel
G M
GM
Schmidt
C J
CJ
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005277:Fenfluramine / Q000494:pharmacology*; D005473:Fluoxetine / Q000494:pharmacology; D007192:Indenes / Q000494:pharmacology; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012022:Reflex, Acoustic / Q000187:drug effects*; D013216:Reflex, Startle / Q000187:drug effects*; D012701:Serotonin / Q000378:metabolism* / Q000502:physiology; D014110:Touch / Q000187:drug effects; D010133:p-Chloroamphetamine / Q000494:pharmacology*
D007192:Indenes; D005473:Fluoxetine; C065434:MDL 27777; D005277:Fenfluramine; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D016202:N-Methylaspartate; D010133:p-Chloroamphetamine